Table 1. . Surface receptor-targeting antibodies in relapsed refractory multiple myeloma.
| Study (year) study design | Number of patients | Antibody | Regimen | Target | Median prior therapies | Dose | Number of cycles | Outcome | Ref. |
|---|---|---|---|---|---|---|---|---|---|
| Vij et al.(2016) Phase II | 97 | Isatuximab SAR650984 | Isatuximab monotherapy | CD38 | 5 (2–14) | 3–10 mg/kg | NR | OR = 24% at dose >10 mg/kg | [12] |
| Martin et al. (2014) Phase Ib | 31 | Isatuximab SAR650984 | Isatuximab + Len + Dex | CD38 | 6 (2–12) | 3, 5, 10 mg/kg | NR | OR = 64.5%; CR = 76.8%; VGPR = 26%; PR = 32%; PFS = 6.2 m | [13] |
| Martin et al. (2014) Phase I | 35 | Isatuximab (SAR650984) | MoAb monotherapy | CD38 | 6 (2–14) | 0.1–20 mg/kg | 5–7 | OR = 32% (>10 mg); PR: n = 6; CR: n = 2 | [11] |
| Kaufman et al. (2013) Phase I | 25 | Milatuzumab | Monotherapy | CD74 | 5 | 1.5–16 mg/kg ×2 or 4 weeks | 8 | No OR; SD = 26% (5/19) >3 m; (1/19)>17 m | [16] |
| Moreau et al. (2011) Phase I | 11 | AVE1642 | AVE1642 + bortezomib | IGF-1 | 4 | 0.5–12 mg/kg + 1.3 mg/m2 | 4 | CR: n = 1; PR: n = 1; SD: n = 3 | [17] |
| 15 | AVE1642 | AVE1642 monotherapy | IGF-1 | 4 | 3–18 mg/kg | 2 | MR: n = 1; SD: n = 7; PD: n = 4 | ||
| Lacy et al. (2008) Phase I | 47 | Figitumumab (CP: 751, 871) | Figitumumab + Dex if no PR on figitumumab monotherapy | IGF-1 | 4 (0–8) | 0.025–20 mg/kg for 4 weeks | 4 | No OR | [18] |
| 27 | Figitumumab (CP: 751, 871) | Figitumumab + Dex | IGF-1 | 4 (0–8) | 0.025–20 mg/kg for 4 weeks + 40 mg/day Dex | PR: n = 6 | |||
| Benson et al. (2015) Phase I | 15 | IPH 2101 | IPH 2101 + Len (10–25 mg) | KIR | 1–2 | 0.2–2 mg/kg | 4 | VGPR = 13%; PR = 20%; MR = 7%; SD = 40%; PD = 20% | [19] |
| Benson et al. (2012) Phase I | 32 | IPH 2101 | Monotherapy | KIR | 2 (1–7) | 0.0003–3 mg/kg every 28 days | 4 | No OR; SD: n = 11 (34%) | [20] |
| Agura et al. (2009) Phase Ib | 36 (33 REP) | Dacetuzumab | Dacetuzumab + Len + Dex | CD40 | 4 | 4–12 mg/kg | 4 | OR = 39%; CR = 3%; PR = 33%; MR = 12%; SD = 30%; PD = 6%; NE = 12% | [21] |
| Hussein et al. (2010) Phase I | 44 | Dacetuzumab | MoAb monotherapy | CD40 | 5 (2–14) | 4–12 mg/kg | 4–5 | SD = 20% | [22] |
| Bensinger et al. (2012) Phase I | 28 | Lucatumumab | MoAb monotherapy | CD40 | NR | 1–6 mg/kg | 4 | SD = 43%; PR = 4% >8 m | [23] |
| Hansson et al. (2015) Phase I | 35 (29 REP) | BI-505 | MoAb monotherapy | ICAM-1 | 6 | 0.0004–20 mg/kg | 1–2 | SD = 24% (2 m); PD = 65% | [24] |
CR: Complete response; Dex: Dexamethasone; ICAM-1: Intercellular adhesion molecule-1; KIR: Killer-cell immunoglobulin like receptor; Len: Lenalidomide; m: Month; MoAb: Monoclonal antibody; MR: Minimal response; NE: Not evaluable; NR: Not reported; OR: Objective response; PD: Progressive disease; PFS: Progression-free survival; PR: Partial response; REP: Response evaluable patient; SD: Stable disease; VGPR: Very good partial response.